3 views left Get unlimited views with a free account

Subscribe to GlobalData Explorer

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Fragile X Syndrome by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 24 ongoing clinical trials involving Fragile X Syndrome
Of the 24 trials,7 trials are in Phase II/III
Furthermore, 6 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Fragile X Syndrome by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Fragile X Syndrome, a Genetic Disorder condition. The largest number of ongoing clinical trials for Fragile X Syndrome is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Fragile X Syndrome-related drug trials.

Zynerba Pharmaceuticals Inc: The leading ongoing Fragile X Syndrome related clinical trial sponsor

Zynerba Pharmaceuticals Inc is the top sponsor for Fragile X Syndrome-related ongoing clinical trials.

Puretech Health Plc, Rowan University, Shionogi & Co Ltd, Autifony Therapeutics Ltd, and University of California Davis are among other notable clinical trial sponsors involved in Fragile X Syndrome. A clinical trial sponsor can be a Company, Government, Individual, or Institution.